Orthopedic Biomaterials Market Hit Double Digit Growth 12.58% Through 2032

In 2022, the orthopedic biomaterials market size was evaluated at USD 82.38 billion and it is expected to contribute USD 212.6 billion in 2030, progressing at a rate of 12.58% of CAGR from 2021 to 2030.

The orthopedic biomaterials market growth is driven by the high occurrences of musculoskeletal disease, rising adoption of technologically advanced products, and growing demand for next-generation biomaterial products that are specifically designed for the requirements of orthopedic procedures.

Market Overview:

A biomaterial is a material that interacts with body tissue and body fluids in order to treat, improve, or repair anatomical parts of the human body. Orthopedic biomaterials are man-made supporting materials that are used for joint replacement, spine replacement, tissue fixation, and orthobiologics. Orthopedics is a branch of medicine that deals with musculoskeletal problems and muscle, bone, and joint disorders. Orthopedic biomaterials are components of tissue repair, tissue replacements, and bone repair supports.

Orthopedic biomaterials are materials that are intended to be implanted into the human body as components of devices that perform specific biological functions by replacing or repairing various tissues such as cartilage, bones, tendons, ligaments, and others. Polymers, ceramics & bioactive glasses, composites, metals, and calcium phosphate are the most common materials used in orthopedic biomaterials. Orthopedic biomaterials are in high demand due to the increasing prevalence of musculoskeletal illnesses, bone fractures, natural joint degradation, and other musculoskeletal disorders. The diseased or traumatized bone has been repaired using biomaterials.

Additionally, the market has grown as a result of increasing numbers of patients opting for knee construction, replacement, and other joint-related orthopedic operations. Furthermore, the orthopedic biomaterials market is being driven by an increase in the number of patients due to an increase in the elderly population, an increase in surgeries, and an increase in health consciousness among the younger generation.

Regional Insights:

North America is expected to dominate the market during the forecast period, due to the rising prevalence of orthopedic surgeries. The increasing number of patients requiring knee replacement or reconstruction and other orthopedic procedures is projected to fuel the growth of the market in the region.

Revenue from the Asia Pacific market is expected to register a rapid CAGR during the forecast period due to the increasing incidence of bone degenerative diseases and bone disorders in developing countries such as China and India. In addition, increasing healthcare expenditure along with improving healthcare infrastructure is expected to drive the growth of the market in this region.

Report Highlights:

• By Material, in 2022, the ceramics & bioactive glass segment is predicted to hold the largest market share owing to the increasing adoption of interbody fusion procedures and various spine surgeries. Moreover, segment expansion is being driven by a surge in synthetic cages and pedicle screws used during fixation operations. Synthetic cages and pedicle screws maintain stability in the target patient pool and boost transplant fusion rates.
• By Application, in 2022, the orthopedic implant segment dominated the market and continued to dominate the market during the forecast period. As per the American Society of Plastic Surgeons, biomaterials are extensively employed for plastic surgeries and the growing demand for plastic surgeries around the world is further boosting the biomaterials market.
• By End User, the hospital segment is expected to expand at a robust growth rate during the forecast period owing to bone and joint-related orthopedic procedures. Older adults require orthopedic biomaterials to be placed in knee replacements, joints, ligaments, and tendons. Such corrected implanting operations are possible in hospitals that have increased segment expansion.

Orthopedic Biomaterials Market Report Scope:

Market Dynamics:

Drivers:

Growing geriatric population

As the world's aging population becomes more vulnerable to joint problems and surgeries, the use of orthopedic biomaterials is expected to rise in the coming years. For instance, According to the report of the United Nations Department of Economic and Social Affairs, In 2019, there were 703 million persons aged 65 years or above in the worldwide population. This figure is expected to increase to 1.5 billion by 2050. The number of people aged 65 and more as a percentage of the global population is expected to rise from 6% currently to 16% by 2050.

Advanced medical facilities are preferred by the aging population for curing orthopedic disorders over repeated visits to clinics and hospitals. The use of orthopedic biomaterials in procedures such as bio-implants. Bioimplants reduce lengthy medical treatments which are desired by the aging population. Chronic illness faced by the geriatric population is often related to joint movements.

Growing use in sports medicine

The rapid rise in sports activities across the globe is boosting young athletes. The increase in athletic activities has been a corresponding escalation in the number of sports injuries, propelling the market expansion of orthopedic device usage. Sports injuries have become more prevalent in recent years, owing to mostly increased engagement in sports as well as active participation in fitness activities. Sports injuries such as stress fractures and torn muscles are usually treated through sports medicine.

Biomaterials are used as implant materials for treating musculoskeletal diseases of bones, muscles, joints, tendons, cartilage, and ligaments. For instance, Injuries involving sports and recreational equipment were treated in emergency departments by 3.2 million persons in 2021. Exercise, cycling, and basketball are the most commonly related to injuries.

Restraint:

Lack of reimbursement policies

Due to the restricted reimbursement policies pertaining to the procedures resulting in reduced reimbursements for orthopedic implants in various countries. Additionally, the lack of reimbursements has put producers under pressure to lower the prices of these products and It is likely to limit the expansion of the orthopedic biomaterials market.

Opportunities:

Advancements in implant technology

Major healthcare manufacturing companies invest heavily in R&D to introduce better treatment resources for their customers, increasing market growth potential. Continuous R&D activities create the opportunity for the introduction of innovative biomaterial products. For instance, in October 2021, Osfirm launched the new implantable Whitlockite Biomaterial. Whitlockite is a magnesium tricalcium phosphate with outstanding bioactive regenerative and reconstructive characteristics as well as great biocompatibility, making it an attractive biomaterial for implant usage on fracture or bone defect sites.

With increased revenue growth, manufacturers in the orthopedic biomaterials industry get an advantage over their competitors by focusing on the development of technologically advanced products. Such effective treatment offers to give great opportunities for the biomaterials industry's growth.

Numerous government and non-government programs

Many government and non-government campaigns are being implemented to increase public awareness about the use of orthopedic biomaterials which is expected to boost the market expansion during the forecast period. Clinical trials have attracted the public's attention, opening up the potential for market investment.

Recent Developments:

• In March 2022, Synergy Biomedical, LLC, a developer of innovative biomaterial products, announced the launch of biosphere® flex sp extremities, synthetic bioactive bone graft. Biosphere® flex sp extremities is a sheet putty consisting of unique spherical bioactive glass grains mixed with a porous collagen/sodium hyaluronate carrier that uses synergy's exclusive biosphere® technology.
• In November 2019, DiFusion, Inc. announced the FDA 510K approval for the Xiphos-ZF spinal interbody device, the first spinal implant developed from a biomaterial called ZFUZE. Many studies have found that the ZFUZE material induces a pro-reparative M2 macrophage response as well as substantial decreases in Interleukin 1-Beta and Interleukin 6.
• In March 2022, Evonik launched osteoconductive VESTAKEEP® Fusion PEEK filament for 3D printed implants that improve fusion between bone and implants.

Major Key Players:

• Acumed, LLC
• Medtronic plc
• Globus Medical, Inc.
• Stryker Corporation
• Koninklijke DSM N.V.
• Exactech, Inc.
• Johnson & Johnson
• Zimmer Biomet
• Wright Medical Group, Inc.
• NuVasive, Inc.

Buy this Research Report@ https://www.precedenceresearch.com/checkout/1107

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com| +1 9197 992 333